Steroids in COVID-19: Tailor-made or "one size fits all"?
Animesh RayAnimesh RayPublished in: Advances in respiratory medicine (2022)
Since the RECOVERY trial, steroids have endorsed by all guidelines for treating moderate-severe COVID-19. The prescribed dose is 6mg dexamethasone or its equivalents for 10 days. However, in clinical practice, there are numerous occasions where the role of steroids cannot be extrapolated from current evidence: patients on immunosuppression, patients with persistent oxygen requirement after ten days of therapy, etc. We highlight the existing caveats and the need for further research and discussion.
Keyphrases
- clinical practice
- coronavirus disease
- sars cov
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- stem cells
- low dose
- high dose
- study protocol
- randomized controlled trial
- high intensity
- phase ii
- patient reported outcomes
- respiratory syndrome coronavirus
- cell therapy
- open label
- drug induced